Technology

MedVanta Partners with Remission Medical to Expand Rheumatology Diagnosis and Care

Published

2 years ago

May 31, 2024

An Innovative and Scalable New Solution for Employers, Payers and Healthcare Organizations Nationwide

RICHMOND, Va. and BETHESDA, Md., May 31, 2024 /PRNewswire/ — MedVanta, the largest physician-owned musculoskeletal (MSK) platform, today announced a new strategic partnership with Remission Medical, the largest national virtual clinic specializing in rheumatology.

MedVanta is the premier MSK platform for providers, employers, payers, and patients, integrating an extensive network with advanced digital solutions for convenient, cost-effective care that boosts workforce health and productivity. As a leader in the shift towards value-based care, MedVanta leverages its high-performance network and proven business model to optimize healthcare delivery. This approach enhances the patient experience and ensures convenient access to high-quality care while reducing cost.

Remission Medical is the largest national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance.

The Centers for Disease Control and Prevention (CDC) reports that one in four U.S. adults suffers from a rheumatic condition, such as arthritis, which is often marked by joint pain and stiffness. With over 150 different rheumatic diseases, diagnosis and management can be complex and challenging.

“Prior authorizations are painful for rheumatologists, slow down care and are circumscribed by the PBMs,” said Blake Wehman, Founder & CEO of Remission Medical. “Our peer-to-peer provider network means we can review orders and reinvent the prior authorization experience, so Time to Treatment Initiation becomes days, not weeks or months. By partnering with MedVanta and drug manufacturers, we aim to disrupt the traditional black box supply chain.”

“This innovative partnership underscores MedVanta’s commitment to leveraging the most advanced technologies to elevate the patient experience, increase accessibility, and efficiently manage healthcare costs,” said Subir Jossan, MD, Chief Transformation Officer at MedVanta. “Our collaboration dramatically shortens diagnosis and treatment timelines for rheumatology patients, helping them achieve and maintain remission.”

Remission Medical and MedVanta’s partnership will offer a first-of-its-kind, vertically integrated stack of services treating everything from back pain to inflammatory arthritis. MedVanta’s comprehensive platform provides a streamlined experience for employers and payers, prioritizing enhanced patient care, improved access to treatment, and cost optimization.

About Remission Medical

Remission Medical is a national virtual rheumatology clinic addressing the full range of rheumatological conditions including Rheumatoid Arthritis, Osteoporosis, Osteoarthritis, Lupus, and Gout, among others. Remission Medical’s providers include state-licensed, board-certified rheumatologists, physician assistants and nurse practitioners with deep expertise in all autoimmune inflammatory conditions.

And Remission Medical is a technology-enabled services rheumatology provider. Built from the ground up for value-based care and value-based benefits, the company’s proprietary platform leverages the power of PRO and generative AI to optimize care pathways and care cadences.

PRESS CONTACT for Remission Medical:

Blake Wehman – blake@remissionmedical.com – www.remissionmedical.com

About MedVanta

MedVanta is the largest physician-owned musculoskeletal (MSK) platform in the nation, offering exceptional opportunities for growth, innovation, and strategic development to its clients and customers. MedVanta addresses the fragmented $600+ billion US musculoskeletal (MSK) market, which suffers from a reactive and costly model, by leveraging an integrated technology platform. This multi-faceted platform digitally connects consumers and patients to a curated network of top-tier MSK providers and ancillary services. By streamlining access to care, enhancing the patient experience, reducing costs, and driving better outcomes, MedVanta transforms the MSK healthcare landscape.

For more information, please visit MedVanta.com or contact us at info@medvanta.com.

PRESS CONTACT for MedVanta:

Katie Santilli
Katie.Santilli@medvanta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/medvanta-partners-with-remission-medical-to-expand-rheumatology-diagnosis-and-care-302160800.html

SOURCE Remission Medical

Technology

IGCS International Announces Strategic Equity Investment by Lacks Enterprises

Published

58 minutes ago

April 22, 2026

DALLAS, April 22, 2026 /PRNewswire/ — IGCS International, a CVE-certified SDVOSB and leading provider of mission support and MRO supplies to the U.S. Department of Defense and federal agencies, today announced that Lacks Enterprises has acquired an equity stake in the company.

The strategic investment combines IGCS’s expertise in government supply chain, logistics, and MRO solutions with Lacks Enterprises’ advanced manufacturing capabilities, including electroplating, injection molding, composites, and testing for aerospace and defense.

“IGCS has built a strong track record supporting the Department of Defense… Partnering with Lacks Enterprises allows us to integrate cutting-edge manufacturing innovation into our offerings,” said Russ Spears, President of IGCS International.

Media Contact: Russ Spears, 214-733-7278, russ@igcsintl.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/igcs-international-announces-strategic-equity-investment-by-lacks-enterprises-302750824.html

SOURCE IGCS International

Technology

Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

Published

58 minutes ago

April 22, 2026

GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026.

Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13759613. A live and archived webcast of the event will be available in the “Investor Relations” section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-to-report-first-quarter-2026-financial-results-on-may-13-2026-302750154.html

SOURCE Shoulder Innovations

Technology

Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

Published

58 minutes ago

April 22, 2026

MADISON, Wis., April 22, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call’s conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 4178502.

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2026.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor and Media Contact
Steve Monroe
VP, Financial Planning & Analysis, Accuray
Investor.relations@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2026-financial-results-on-may-6-2026-302750641.html

SOURCE Accuray Incorporated